Black Diamond Therapeutics reports Q1 diluted EPS 98c vs. (35c) last year

Black Diamond ended Q1 with approximately $152.4M in cash, cash equivalents, and investments compared to $98.6M as of December 31, 2024, , which the company believes is sufficient to fund its anticipated operating expenses and capital expenditure requirements into Q4 of 2027. “We continue to execute on enrollment in our BDTX-1535 Phase 2 trial for the treatment of newly diagnosed patients with EGFRm NSCLC and look forward to providing a clinical update in the fourth quarter of 2025,” said Mark Velleca, M.D., Ph.D., CEO. “Our recently announced global licensing agreement with Servier for BDTX-4933 provides us with a strong cash position and runway into the fourth quarter of 2027. Pending FDA feedback in the fourth quarter of 2025, we believe we are well-positioned to begin pivotal development of BDTX-1535 in the first half of 2026.”